Irinotecano

Irinotecan, the active ingredient in Irinotecano, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, metastatic colorectal cancer and as adjuvant therapy for colon cancer in adult patients. GNH USA supplies Irinotecano as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is used in colorectal cancer treatment pathways and related disease settings. - Colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. - Metastatic colorectal cancer: provides disease control in combination chemotherapy protocols. - Adjuvant therapy for colon cancer: reduces risk of recurrence after surgical resection.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often early and may be severe. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Neutropenia: reduced white blood cell count. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Febrile neutropenia: infection risk with fever. - Severe colitis or ileus: life‑threatening intestinal toxicity. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: anaphylaxis or severe hypersensitivity.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity. - Pregnancy: Category D – avoid use unless potential benefit justifies the risk. - Breastfeeding: Not recommended; drug may be excreted in milk. - Hepatic impairment: Use with caution and monitor liver function tests. - Renal impairment: Dose adjustment may be required based on renal function. - Drug interactions: Review concomitant medications for CYP3A4 modulators and UGT1A1 status. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several agents that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase systemic exposure and toxicity. - UGT1A1*28 homozygous genotype: heightened risk of severe neutropenia and diarrhea. - High‑dose warfarin: potential for increased bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may reduce drug exposure and effectiveness. - Dexamethasone‑containing antiemetics: can affect metabolism pathways. - Concurrent neutropenia‑inducing agents: require close blood count monitoring.